Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays

References

• Druker BJ Guilhot FO O’Brien SG IRIS Investigators Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 2006 355 23 2408 2417 17151364
   PubMed Web of Science ®Google Scholar
• Titier K Picard S Ducint D Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry Ther Drug Monit 2005 27 5 634 640 16175138
   PubMed Web of Science ®Google Scholar
• Kantarjian HM Talpaz M Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias Semin Oncol 2001 28 5 Suppl 7 9 18 11740802
   PubMed Web of Science ®Google Scholar
• Guilhot F Hughes T Cortes J Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial Haematologica 2012 97 5 731 738 22315495
   PubMed Web of Science ®Google Scholar
• Awidi A Salem II Najib N Mefleh R Tarawneh B Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods comparison Leuk Res 2010 34 6 714 717 19744707
   PubMed Web of Science ®Google Scholar
• Guilhot F Roy L Tomowiak C Current treatment strategies in chronic myeloid leukemia Curr Opin Hematol 2012 19 2 102 109 22227529
   PubMed Web of Science ®Google Scholar
• Parise RA Ramanathan RK Hayes MJ Egorin MJ Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma J Chromatogr B Analyt Technol Biomed Life Sci 2003 791 1–2 39 44
   PubMed Web of Science ®Google Scholar
• Mičová K Friedecký D Faber E Polýnková A Adam T Flow injection analysis vs ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma Clin Chim Acta 2010 411 23–24 1957 1962 20713033
   PubMed Web of Science ®Google Scholar
• Roth O Spreux-Varoquaux O Bouchet S Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS Clin Chim Acta 2010 411 3–4 140 146 19853594
   PubMed Web of Science ®Google Scholar
• Davies A Hayes AK Knight K Watmough SJ Pirmohamed M Clark RE Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography Leuk Res 2010 34 6 702 707 20004471
   PubMed Web of Science ®Google Scholar
• Solassol I Bressolle F Philibert L Charasson V Astre C Pinguet F Liquid chromatography-electrospray mass spectrometry determination of imatinib and its main metabolite, N-desmethyl-imatinib in human plasma J Liq Chromatogr Relat Technol 2006 29 2957 2974
   Web of Science ®Google Scholar
• Bakhtiar R Khemani L Hayes M Bedman T Tse F Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry J Pharm Biomed Anal 2002 28 6 1183 1194 12049982
   PubMed Web of Science ®Google Scholar
• Miura M Takahashi N Sawada KI Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection J Chromatogr Sci 2011 49 5 412 415 21549035
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Guidance for industry: bioanalytical method validation Rockville, MD Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research 2001 Available from: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf Accessed June 6, 2013
   Google Scholar
• ANVISA Resolution RE No. 899, of May 29, 2003. Brazil, Brazilian National Surveillance Agency (ANVISA); Diário Oficial da União 02/jun/2003 Available on line: http://www.in.gov.br/visualiza/index.jsp?jornal=1&pagina=56&data=02/06/2003 Accessed June 2, 2013
   Google Scholar
• ANVISA Resolution RDC No. 27, of May 27, 2012. Brazil, Brazilian National Surveillance Agency (ANVISA); Diário Oficial da União 22/may/2012 Available from: http://www.in.gov.br/visualiza/index.jsp?data=22/05/2012&jornal=1&pagina=93&totalArquivos=192 Accessed June 2, 2013
   Google Scholar
• Vessman J Stefan RI Staden JF Selectivity in analytical chemistry (IUPAC Recommendations 2001) Pure Appl Chem 2001 73 8 1381 1386
   Web of Science ®Google Scholar
• Hubert P Chiap P Crommen J The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory Anal Chim Acta 1999 391 2 135 148
   Web of Science ®Google Scholar
• Matuszewski BK Constanzer ML Chavez-Eng CM Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS Anal Chem 2003 75 13 3019 3030 12964746
   PubMed Web of Science ®Google Scholar
• BIPM Joint Committee for Guides in Metrology (JCGM) Bureau of Weights and Measures (BIPM) International vocabulary of metrology — Basic and general concepts and associated terms (VIM) JCGM 200 2012 Joint Committee for Guides in Metrology, Bureau of Weights and Measures (BIPM) 2012 Available from: http://www.bipm.org/utils/common/documents/jcgm/JCGM_200_2012.pdf Accessed June 2, 2013
   Google Scholar
• Currie LA Nomenclature in evaluation of analytical methods including detection and quantification capabilities (IUPAC Recommendations 1995) Pure Appl Chem 1995 67 10 1699 1723
   Web of Science ®Google Scholar
• Rezende VM Rivellis AJ Gomes MM Determination of serum imatinib mesylate in chronic myeloid leukemia patients: validation and application of a new analytical method to control therapy adherence Rev Bras Hematol Hemoter 2013 35 2 103 108 23741187
   PubMedGoogle Scholar
• Annesley TM Ion suppression in mass spectrometry Clin Chem 2003 49 7 1041 1044 12816898
   PubMed Web of Science ®Google Scholar
• Cortes J Giles F O’Brien S Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha Blood 2003 102 1 83 86 12637317
   PubMed Web of Science ®Google Scholar
• Cortes JE Baccarani M Guilhot FO Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study J Clin Oncol 2010 28 3 424 430 20008622
   PubMed Web of Science ®Google Scholar
• Parrillo-Campiglia S Ercoli MC Umpierrez O Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers Clin Ther 2009 31 10 2224 2232 19922893
   PubMed Web of Science ®Google Scholar
• Larson RA Druker BJ Guilhot F Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study Blood 2008 111 8 4022 4028 18256322
   PubMed Web of Science ®Google Scholar